TAOX
TAO Synergies Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.89
−4.07%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 772.5K | 299.1K | — | — | — |
| Cost of Revenue | 735.00 | — | — | — | — |
| Gross Profit | 771.8K | 299.1K | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 173.3K | 322.2K | 1.6M | 2.0M | 6.3M |
| SG&A Expense | 9.0M | 9.0M | 5.2M | 6.3M | 9.8M |
| General & Admin Expense | 7.5M | 9.0M | 5.2M | 6.3M | 9.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 9.2M | 9.3M | 6.8M | 8.3M | 16.1M |
| Cost and Expenses | 9.2M | 9.3M | 6.8M | 8.3M | 16.1M |
| Operating Income (EBIT) | (8.4M) | (9.0M) | (6.8M) | (8.3M) | (16.1M) |
| Non-Operating | |||||
| Interest Income | 168.5K | 442.9K | 1.3M | 1.6M | 335.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 168.5K | 442.9K | 1.3M | 1.6M | 335.0K |
| Other Non-Op Income/Expense | (8.3M) | (19.7M) | (6.0M) | 2.3M | 10.6M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (16.7M) | (28.7M) | (12.8M) | (6.0M) | (5.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (16.7M) | (28.7M) | (12.8M) | (6.0M) | (5.6M) |
| Earnings from Cont. Ops | (16.7M) | (28.7M) | (12.8M) | (6.0M) | (5.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (22.1M) | (29.1M) | (13.6M) | (13.8M) | (5.7M) |
| Per Share | |||||
| Basic EPS | ($3.98) | ($8.81) | ($10.99) | ($29.56) | ($20.25) |
| Diluted EPS | ($4.00) | ($8.81) | ($10.99) | ($29.56) | ($20.25) |
| Revenue Per Share | $0.10 | $0.09 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 7.5M | 3.3M | 1.2M | 466100 | 279568 |
| Diluted Shares Outstanding | 7.5M | 3.3M | 1.2M | 466100 | 279568 |
| Profitability Metrics | |||||
| EBITDA | (8.4M) | (9.0M) | (6.8M) | (8.3M) | (16.1M) |
| D&A | 3.2K | 3.6K | 5.6K | 6.3K | 5.7K |
| EBIT | (8.4M) | (9.0M) | (6.8M) | (8.3M) | (16.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026